[Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS trial): long-term results of a single-arm, prospective trial with comparison to surgery]
- PMID: 34928434
- PMCID: PMC8789709
- DOI: 10.1007/s00066-021-01893-z
[Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS trial): long-term results of a single-arm, prospective trial with comparison to surgery]
Comment on
-
Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery.Lancet Oncol. 2021 Oct;22(10):1448-1457. doi: 10.1016/S1470-2045(21)00401-0. Epub 2021 Sep 13. Lancet Oncol. 2021. PMID: 34529930 Free PMC article. Clinical Trial.
References
-
- Franks KN, McParland L, Webster J, Baldwin DR, Sebag-Montefiore D, Evison M, et al. SABRTooth: a randomised controlled feasibility study of stereotactic ablative radiotherapy (SABR) with surgery in patients with peripheral stage I nonsmall cell lung cancer considered to be at higher risk of complications from surgical resection. Eur Respir J. 2020;56:2000118. doi: 10.1183/13993003.00118-2020. - DOI - PubMed
-
- Zhao J, Yorke ED, Li L, Kavanagh BD, Li XA, Das S, et al. Simple factors associated with radiation-induced lung toxicity after stereotactic body radiation therapy of the thorax: a pooled analysis of 88 studies. Int J Radiat Oncol Biol Phys. 2016;95:1357–1366. doi: 10.1016/j.ijrobp.2016.03.024. - DOI - PMC - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
